Efficacy and safety of the combination of lapatinib plus capecitabine for HER2-positive advanced breast cancer.

被引：0
|
作者：
Aravantino-Fatorou, E.
Christodoulou, C.
Nikolakopoulou, A.
Galani, E.
Klouvas, G.
Acholos, V.
Karapanagiotidis, G.
Batziou, E.
Tsakalos, G.
Skarlos, D.
机构：
[1] Metropolitan Hosp, Athens, Greece
[2] Hellen Cooperat Oncol Grp Data Off, Athens, Greece
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e11520
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11520
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Lapatinib plus capecitabine for HER2-positive advanced breast cancer
    Geyer, Charles E.
    Forster, John
    Lindquist, Deborah
    Chan, Stephen
    Romieu, C. Gilles
    Pienkowski, Tadeusz
    Jagiello-Gruszfeld, Agnieszka
    Crown, John
    Chan, Arlene
    Kaufman, Bella
    Skarlos, Dimosthenis
    Campone, Mario
    Davidson, Neville
    Berger, Mark
    Oliva, Cristina
    Rubin, Stephen D.
    Stein, Steven
    Cameron, David
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (26): : 2733 - 2743
  • [2] Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer:efficacy,safety,and biomarker results from Chinese patients
    Daniel Chua
    Winnie Yeo
    Beth Newstat
    Alka Preston
    Anne-Marie Martin
    [J]. 癌症, 2011, 30 (05) : 327 - 335
  • [3] Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer
    Kaufman, Bella
    Stein, Steven
    Casey, Michelle A.
    Newstat, Beth O.
    [J]. BIOLOGICS-TARGETS & THERAPY, 2008, 2 (01): : 61 - 65
  • [4] Lapatinib plus capecitabine for HER2-positive advanced breast cancer (vol 355, pg 2733, 2006)
    Geyer, C. E.
    Forster, J.
    Lindquist, D.
    Chan, S.
    Romieu, C. G.
    Pienkowski, T.
    Jagiello-Gruszfeld, A.
    Crown, J.
    Chan, A.
    Kaufman, B.
    Skarlos, D.
    Campone, M.
    Davidson, N.
    Berger, M.
    Oliva, C.
    Rubin, S. D.
    Stein, S.
    Cameron, D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (14): : 1487 - 1487
  • [5] Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review
    Madden, Rebecca
    Kosari, Sam
    Peterson, Gregory M.
    Bagheri, Nasser
    Thomas, Jackson
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2018, 56 (02) : 72 - 80
  • [6] Lapatinib plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer
    Watanabe, J.
    Hamauchi, S.
    Higashi, Y.
    Onozawa, Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer
    Oliveira, Mafalda
    Garrigos, Laia
    Assaf, Juan David
    Escriva-de-Romani, Santiago
    Saura, Cristina
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (09) : 731 - 741
  • [8] Clinical recommendations for the use of lapatinib ditosylate plus capecitabine for patients with advanced or metastatic HER2-positive breast cancer
    Snyder, Raymond D.
    Boyle, Frances M.
    Chan, Arlene
    Craft, Paul S.
    De Boer, Richard
    Mainwaring, Paul N.
    McCarthy, Nicole J.
    Wilcken, Nicholas R.
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2009, 5 (01) : 4 - 16
  • [9] Efficacy of Lapatinib Plus Capecitabine After TDM-1 in HER2-Positive Metastatic Breast Cancer Patients
    Dogan, Izzet
    Yildiz, Anil
    Ahmed, Melin Aydan
    Vatansever, Sezai
    [J]. INDIAN JOURNAL OF SURGICAL ONCOLOGY, 2024, 15 (03) : 489 - 494
  • [10] Assessment of the efficacy and safety of lapatinib in combination with capecitabine in patients with metastatic HER2-positive breast cancer treated in Centrum Onkologii Ziemi Lubelskiej
    Staroslawska, Elzbieta
    Czerepinska, Anna
    Chrzanowska-Kapica, Agata
    Czarnocki, Krzysztof
    [J]. WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2010, 14 (02): : 79 - 86
12345